Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial (vol 22, 960, 2022)Abolghasem Allahyari,Ali Ehsanpour, Behrouz Najafi, Nafseh Ansarinejad,Valiollah Mehrzad,Behjat Kalantari,Jahangir Raafat,Mojtaba Ghadiany,Farhad Shahi,Behrooz Gharib,Vahid Moazed,Adnan Khosravi,Mir Hossein Mirpour,Sina Salari,Seyedmohammadreza Mortazavizadeh,Amirabbas Nekoyi,Mohsen Khani,Alireza Sadeghi,Sirus Gharib,Alireza Bary,Mehrzad Mirzania,Shirin Haghighat,Seyed Mohsen Razavi,Seyed Amir Hossein Emami,Mehran Hosseinzadeh,Mahdi Mirbolouk,Sanambar Sadighi,Abdolali Shahrasbi,Ali Esfahani,Masoumeh Gity,Nassim Anjidani, Hamidreza Kaf,Safa NajafBMC CANCER（2022）引用 0|浏览12暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
